These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 16532723

  • 1. [Heart rate: a cardiovascular risk factor that can no longer be ignored].
    Palatini P.
    G Ital Cardiol (Rome); 2006 Feb; 7(2):119-28. PubMed ID: 16532723
    [Abstract] [Full Text] [Related]

  • 2. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy.
    Palatini P, Benetos A, Julius S.
    Drugs; 2006 Feb; 66(2):133-44. PubMed ID: 16451089
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety of antihypertensive therapy.
    Grossman E, Messerli FH.
    Prog Cardiovasc Dis; 2006 Feb; 49(1):16-25. PubMed ID: 16867847
    [Abstract] [Full Text] [Related]

  • 4. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC.
    Br Med Bull; 2009 Feb; 90():71-84. PubMed ID: 19474056
    [Abstract] [Full Text] [Related]

  • 5. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM, Vitale C, Volterrani M.
    Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
    [Abstract] [Full Text] [Related]

  • 6. Significance of reduction in heart rate in cardiovascular disease.
    Hjalmarson A.
    Clin Cardiol; 1998 Dec; 21(12 Suppl 2):II3-7. PubMed ID: 9853192
    [Abstract] [Full Text] [Related]

  • 7. [Hypertension--heart rate and cardiovascular risk].
    Bénétos A.
    Arch Mal Coeur Vaiss; 2000 Nov; 93(11 Suppl):1371-6. PubMed ID: 11190282
    [Abstract] [Full Text] [Related]

  • 8. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

  • 9. Significance, prognostic value and management of heart rate in hypertension.
    Courand PY, Lantelme P.
    Arch Cardiovasc Dis; 2014 Jan; 107(1):48-57. PubMed ID: 24439523
    [Abstract] [Full Text] [Related]

  • 10. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 11. Heart rate distribution and predictors of increased heart rate among French hypertensive patients with stable coronary artery disease. Data from the LHYCORNE cohort.
    Lorgis L, Zeller M, Jourdain P, Beaune J, Cambou JP, Vaisse B, Chamontin B, Cottin Y.
    Arch Cardiovasc Dis; 2009 Jul; 102(6-7):541-7. PubMed ID: 19664574
    [Abstract] [Full Text] [Related]

  • 12. The management of hypertension in ischaemic heart disease.
    Hawkins NM, Dunn FG.
    Curr Opin Cardiol; 2006 Jul; 21(4):273-8. PubMed ID: 16755194
    [Abstract] [Full Text] [Related]

  • 13. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B, Devereux RB, Kjeldsen SE, Lyle PA, Zhang Z, Edelman JM.
    Blood Press; 2007 Jul; 16(1):6-12. PubMed ID: 17453746
    [Abstract] [Full Text] [Related]

  • 14. Elevated heart rate in cardiovascular diseases: a target for treatment?
    Palatini P.
    Prog Cardiovasc Dis; 2009 Jul; 52(1):46-60. PubMed ID: 19615493
    [Abstract] [Full Text] [Related]

  • 15. [Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
    Baumgart P.
    MMW Fortschr Med; 2006 Mar 16; 148(11):57, 59-60. PubMed ID: 16612965
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cardiovascular drugs: effects on exercise testing and exercise training of the coronary patient.
    Wenger NK.
    Cardiovasc Clin; 1985 Mar 16; 15(2):133-43. PubMed ID: 2868791
    [Abstract] [Full Text] [Related]

  • 18. Heart rate in coronary syndromes and heart failure.
    Orso F, Baldasseroni S, Maggioni AP.
    Prog Cardiovasc Dis; 2009 Mar 16; 52(1):38-45. PubMed ID: 19615492
    [Abstract] [Full Text] [Related]

  • 19. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials.
    Cucherat M.
    Eur Heart J; 2007 Dec 16; 28(24):3012-9. PubMed ID: 17981830
    [Abstract] [Full Text] [Related]

  • 20. Progress in cardiovascular diseases: cognitive function in essential hypertension.
    Birkenhäger WH, Staessen JA.
    Prog Cardiovasc Dis; 2006 Dec 16; 49(1):1-10. PubMed ID: 16867845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.